Veterinarian Guide to Cannabis: What Vets Need to Know
A comprehensive guide for veterinarians on cannabis therapeutics in veterinary medicine. Legality, clinical evidence, drug interactions, client communication, and professional considerations.
Veterinary Disclaimer
This information is for educational purposes only and does not constitute veterinary medical advice. CBD products for pets are not FDA-approved. Always consult a licensed veterinarian before giving any cannabis-derived product to your pet. Do not use this information to replace professional veterinary care.
Overview
Cannabis therapeutics represents one of the most rapidly evolving areas in veterinary medicine. As pet owners increasingly seek information about CBD and other cannabinoids for their animals, veterinarians face the challenge of providing evidence-based guidance in a landscape where clinical data is still emerging and legal frameworks vary by jurisdiction. This guide synthesizes the current state of veterinary cannabis science, regulatory considerations, and practical guidance for veterinary professionals.
The legal landscape for veterinarians discussing cannabis with clients has shifted significantly in recent years. California's AB 2215 (2018) was the first law explicitly protecting veterinarians from disciplinary action for discussing cannabis with clients. Several other states have followed suit. However, veterinarians in most jurisdictions cannot prescribe, recommend, or dispense cannabis products. Understanding the distinction between discussing cannabis and recommending it is essential for veterinary professionals navigating this space.
What You Need to Know
The clinical evidence base for cannabinoid therapeutics in veterinary medicine, while growing, remains limited. The strongest evidence exists for CBD in canine osteoarthritis (Gamble et al., 2018; Verrico et al., 2020) and canine idiopathic epilepsy (McGrath et al., 2019). These studies used pharmaceutical-grade CBD oil at doses of 2-2.5 mg/kg twice daily and showed statistically significant improvements in pain scores and seizure frequency respectively. Smaller studies and case reports suggest potential benefits in feline conditions, anxiety disorders, and palliative care, but these require larger controlled trials for confirmation.
Drug interactions are a primary concern for veterinarians when clients report CBD use. CBD is a potent inhibitor of CYP2D6 and CYP3A4 enzymes, which metabolize numerous veterinary pharmaceuticals. Clinically significant interactions may occur with phenobarbital (increased plasma levels), clobazam (increased levels of active metabolite), ciclosporin, NSAIDs, and certain chemotherapy agents. Veterinarians should monitor drug levels and liver function when patients are receiving both CBD and medications processed by these enzyme pathways.
Client communication about cannabis requires balancing scientific honesty with practical guidance. Many clients are already using CBD products for their pets and may not disclose this if they anticipate judgment. Creating a non-judgmental environment where clients feel comfortable disclosing supplement use, including CBD, allows veterinarians to monitor for interactions and adverse effects. When discussing CBD, veterinarians can share what the current research shows, emphasize the importance of product quality and COAs, and explain that evidence is still limited for most applications.
Professional organizations have begun addressing cannabis in veterinary medicine. The American Veterinary Medical Association (AVMA) has called for rescheduling cannabis to facilitate research while cautioning against unsubstantiated claims. The Veterinary Cannabis Society provides continuing education resources for practitioners. Several veterinary schools now include endocannabinoid science in their curricula. Veterinarians interested in cannabis therapeutics should seek out evidence-based continuing education, stay current with emerging research, and understand their state's specific regulations regarding veterinary cannabis discussions.
Dosing Guidance
For veterinary professionals: the most studied dosing protocols are CBD at 2 mg/kg PO BID for osteoarthritis (Gamble et al.) and 2.5 mg/kg PO BID as add-on therapy for idiopathic epilepsy (McGrath et al.). Start at 1 mg/kg BID and titrate upward over 2-4 weeks based on clinical response. Recommend baseline CBC, chemistry panel, and liver enzymes before starting CBD, with follow-up bloodwork at 4-6 weeks and every 6 months during ongoing use. Monitor ALP specifically, as elevations are commonly observed. Advise clients to use products with batch-specific third-party COAs from ISO-accredited laboratories.
Safety Warnings
- ⚠Veterinarians should be aware that many over-the-counter pet CBD products are inaccurately labeled. Studies consistently show that actual CBD content can vary by 50-150% from label claims. Recommend only products with current, batch-matched COAs from ISO 17025-accredited laboratories.
- ⚠THC toxicity cases are increasing as cannabis legalization expands. Veterinarians should maintain a current toxicology reference for cannabis and be prepared to provide supportive care. Most cases resolve within 12-36 hours with IV fluids, temperature management, and monitoring.
- ⚠The legal landscape for veterinarians discussing cannabis varies by state. Check your state veterinary medical board's current position before initiating cannabis conversations with clients. Document cannabis discussions and any recommendations in the medical record.
- ⚠This information is for educational purposes only and does not constitute veterinary medical advice. CBD products for pets are not FDA-approved. Always consult a licensed veterinarian before giving any cannabis-derived product to your pet. Do not replace professional veterinary care with information found on this page.
Frequently Asked Questions
Can veterinarians legally recommend CBD for pets?
This varies by state. In California, Nevada, and several other states, veterinarians are specifically protected from disciplinary action for discussing cannabis with clients. However, most states do not allow veterinarians to prescribe, recommend, or dispense cannabis products. Veterinarians can generally discuss the current research, explain how the endocannabinoid system works, and advise on product quality without making specific therapeutic recommendations. Check your state veterinary medical board's guidelines.
What should I monitor in patients using CBD?
Recommended monitoring includes: baseline and follow-up CBC, serum chemistry panel, and liver enzymes (ALP elevations are common with CBD use); plasma drug levels for patients on phenobarbital or other anti-seizure medications (CBD can increase drug levels); clinical signs of excessive sedation or gastrointestinal upset; and owner-reported assessments of the target condition using standardized scoring systems when available.
How should I handle client questions about cannabis for their pet?
Approach cannabis discussions with the same evidence-based framework used for any therapeutic question. Acknowledge the client's interest, share what the current research demonstrates, be transparent about the limitations of available evidence, emphasize the importance of product quality and COAs, and discuss potential drug interactions with any current medications. Creating a judgment-free environment encourages clients to disclose supplement use, which supports better patient care.